Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-07-15
2010-02-16
Carlson, Karen Cochrane (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000
Reexamination Certificate
active
07662774
ABSTRACT:
A method for prophylactically or therapeutically treating sepsis or septic shock is described, wherein an inhibitor to tissue factor is administered to septic patients. Additionally, a method for treating inflammation is described wherein the inhibitor is administered to patients. This inhibitor is termed lipoprotein associated coagulation inhibitor, or commonly LACI. It is 38 kD and has 276 amino acids. LACI has now been shown to be useful for the treatment of sepsis, septic shock and inflammation.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4399216 (1983-08-01), Axel et al.
patent: 4495285 (1985-01-01), Shimizu et al.
patent: 4511502 (1985-04-01), Builder et al.
patent: 4530787 (1985-07-01), Shaked et al.
patent: 4569790 (1986-02-01), Koths et al.
patent: 4572798 (1986-02-01), Koths et al.
patent: 4603106 (1986-07-01), Cerami et al.
patent: 4609546 (1986-09-01), Hiratani
patent: 4620948 (1986-11-01), Builder et al.
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4711845 (1987-12-01), Gelfand et al.
patent: 4748234 (1988-05-01), Dorin et al.
patent: 4766106 (1988-08-01), Katre et al.
patent: 4847201 (1989-07-01), Kawasaki et al.
patent: 4929700 (1990-05-01), Halenbeck et al.
patent: 4966852 (1990-10-01), Wun et al.
patent: 5106833 (1992-04-01), Broze et al.
patent: 5110730 (1992-05-01), Edgington et al.
patent: 5219994 (1993-06-01), Buonassisi et al.
patent: 5223427 (1993-06-01), Edgington et al.
patent: 6063764 (2000-05-01), Creasey
patent: 268110 (1988-05-01), None
patent: 270799 (1988-06-01), None
patent: 318451 (1989-05-01), None
patent: 473564 (1992-03-01), None
patent: WO 85/04899 (1985-11-01), None
patent: 90/08158 (1990-07-01), None
patent: 91/02753 (1991-03-01), None
patent: WO 91/19514 (1991-12-01), None
patent: 92/07584 (1992-05-01), None
patent: WO 93/25230 (1993-12-01), None
Record, Kenneth E., Chapter 87/Gram-Negative Sepsis and Septic Shock, Pharmacotherapy, A Pathophysiologic Approach, Editors, DiPiro, New York, (1989), pp. 1258-1265.
Stedman's Medical Dictionary, 25th Edition, Williams & Wilkin's, Baltimore, (1990), p. 1268.
Ameri et al., “Expression of Tissue Factor Pathway Inhibitor by Cultured Endothelial Cells in Response to Inflammatory Mediators”,Blood, 79:3219-26 (1992).
Bailey et al, “Methylmercury as a Reversible Denaturing Agent for Agarose Gel Electrophoresis”,Anal. Bioch., 70:75 (1976).
Bajaj et al., “Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: Evidence that endothelium is the principal site of its synthesis”,PNAS(USA), 87:8869-73 (1990).
Bajaj et al., “Inhibitor of the Factor VIIa-Tissue Factor Complex is Reduced in Patients with Disseminated Intravascular Coagulation but Not in Patients with Severe Hepatocellular Disease”,J. Clin. Invest., 79:1874 (1987).
Bevilacqua et al., “Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin 1 ”,PNAS(USA), 83:4533-37 (1986).
Bolivar et al., “Construction and Characterization of New Cloning Vehicles”,Gene, 2:95 (1977).
Bone et al., “Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis”,Chest, 101:1644-1655 (1992).
Broach, “Construction of High Copy Yeast Vectors Using 2-μm Circle Sequences”,Meth. Enzymol., 101:307 (1983).
Broach, “Transformation in Yeast: Development of a Hybrid Cloning Vector and Isolation of theCAN1Gene”,Gene, 8:121 (1979).
Broze et al., “Regulation of Coagulation by a Multivalent Kunitz-Type Inhibitor”,Biochemistry, 29: 7539-46 (1990).
Broze et al., “The Lipoprotein-Associated Coagulation Inhibitor That Inhibits the Factor VII-Tissue Factor Complex Also Inhibits Factor Xa: Insight Into Its Possible Mechanism of Action”,Blood, 71:335-343 (1988).
Broze et al., “Isolation of the tissue factor inhibitor produced by HepG2 bepatoma cells”,PNAS(USA), 84:1886-1890 (1987).
Clarke et al., “Selection Procedure for Isolation of Centromere DNAs fromSaccharomyces cerevisiae ”, Meth. Enzymol., 101:300 (1983).
Clewell et al., “Nature of Col E, Plasmid Replication inEscherichia coliin the Presence of Chloramphenicol”,J. Bacteriol., 110.-667 (1972).
Clewell et al, “Supercoiled Circular DNA-Protein Complex inEscherichia Coli: Purification and Induced Conversion to an Open Circular DNA Form”,PNAS(USA). 62:1159 (1969).
Cohen et al, “Nonchromosomal Antibiotic Resistance in Bacteria: Genetic Transformation ofEscherichia coliby R-Factor DNA”,PNAS(USA). 69:2110 (1972).
Colucci et al., “Cultured Human Endothelial Cells Generate Tissue Factor in Response to Endotoxin”,J. Clin. Invest., 71:1893-96 (1983).
Corrigan, “Heparin therapy in bacterial septicemia”,J. Pediatrics. 91:695 (1977).
Creasey et al., “Tissue Factor Pathway Inhibitor Reduces Mortality fromEscherichia coilSeptic Shock”,J. Clin. Invest., 91:2850-56 (1993).
Creasey et al., “Endotoxin and Cytokine Profile in Plasma of Baboons Challenged With Lethal and SublethalEscherichia coil”, Circ. Shock, 33:84-91 (1991).
Cross et al., “Choice of Bacteria in Animal Models of Sepsis”,Infect. Immun., 61:2741-47 (1993).
Day et al., “Recombinant Lipoprotein-Associated Coagulation Inhibitor Inhibits Tissue Thromboplastin-Induced Intravascular Coagulation in the Rabbit”,Blood, 76:1538-1545 (1990).
Depicker et al, “Nopaline Synthase: Transcript Mapping and DNA Sequence”,J. Mol. Appl. Gen.1:561 (1982).
Expanded Antril data fails to impress investors, Biotechnology Business News, Mar. 26, 1993.
Fiers et al., “Complete nucleotide sequence of SV40 DNA”,Nature, 273:113 (1978).
Fink et al, “Laboratory Models of Sepsis and Septic Shock”,J. Surgical Res., 49:186-196(1990).
Fischer et al., “Interleukin-I Receptor Blockade Improves Survival and Hemodynamic Performance inEscherichia coilSeptic Shock, But Falls to Alter Host Responses to Sublethal Endotoxemia”,J. Clin. Invest., 89:1551-1557 (1992).
Fitzer-Schiller, “Synergen Stock Falls Again on Delay in Marketing Application”, The Reuter Business Report, Mar. 23, 1993.
Goeddel et al., “Synthesis of human fibroblast interferon byE. coil”, Nucl. Acids Res.. 8:4057 (1980).
Graham et al., “A New Technique for the Asszy of Infectivity of Human Adenovirus 5 DNA”,Virology, 52:456 (1973).
Hess et al., “Cooperation of Glycolytic Enzymes”,J. Adv. Enzyme Reg., 7:149 (1968).
Hinshaw et al., “Detection of the ‘Hyperdynamic State’ of Sepsis in the Baboon during LethalE. coilInfusion”,J . Trauma, 23:361-365 (1983).
Hinshaw et al, “Survival of Primates in LD100Septic Shock Following Therapy with Antibody to Tumor Necrosis Factor (TNFα)”,Circulatory Shock, 30:279-292 (1990).
Hitzeman et al., “Isolation and Characterization of the Yeast 3- Phosphoglycerokinase Gene (PGk) by an Immunological Screening Technique”,J. Biol. Chem., 255:12073 (1980).
Holland et al., “The Primary Structures of Two Yeast Enolase Genes”,J. Biol. Chem., 256:1385 (1981).
Holland et al., “Isolation and Identification of Yeast Messenger Ribonucleic Acids Coding for Enolase, Glyceraldehyde-3-phosphate Dehydrogenase, and Phosphogiycerate Kinase”,Biochemisary, 17:4900 (1978).
Hsiao et al., “High-frequency transformation of yeast by plasmids containing the cloned yeast ARG4 gene”,PNAS(USA) 76:3829 (1979).
Knauf et al., “Relationship of Effective Molecular Size to Systemic Clearance in Rats of Recombinant Interleukin-2 Chemically Modified with Water-Soluble Polymers”,J. Biol. Chem., 263:15064 (1988).
Lyberg et al., “Cellular cooperation in endothelial cell thromboplasti
Broze George J.
Creasey Abla A.
Banner & Witcoff , Ltd.
Carlson Karen Cochrane
Novartis Vaccines and Diagnostics Inc.
LandOfFree
Method for using lipoprotein associated coagulation... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for using lipoprotein associated coagulation..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for using lipoprotein associated coagulation... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4182535